Br J Clin Pharmacol. 2021 Jun 29. doi: 10.1111/bcp.14959. Online ahead of print.
Both Apixaban and Enoxaparin are FDA approved standard therapy for prophylaxis of DVT, however, the superiority of one over another is still controversial With an objective to observe efficacy and safety outcomes of Apixaban and Enoxaparin in patients undergoing THA and TKA 96 patients undergoing THA/TKA (October 2018 to August 2019) were randomly allocated into 2 groups; (n=48) Apixaban and (n=48) Enoxaparin. Efficacy outcomes and safety outcomes were recorded at 2 weeks/5 weeks post TKA/THA. Follow-up functional scoring was done at 6 months postoperatively. Apixaban and Enoxaparin were found to be equally efficacious in preventing VTE, however Apixaban had a better safety profile. Apixaban group had non-significant higher tendency for wound discharge, AF and TIA. Enoxaparin had non-significant greater tendency for bleeding, wound dehiscence and pulmonary complications. Apixaban is a safe alternative to conventionally used Enoxaparin for chemoprophylaxis in patients undergoing THA or TKA.